Jonathan Goldman is Professor of Medicine, Hematology/Oncology Division at UCLA. OpenAlex indexes 792 publications with 34,790 citations (h-index 68); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Jonathan W. Goldman, MD, is Professor of Medicine, Hematology/Oncology Division at UCLA (David Geffen School of Medicine / UCLA Health). The public record shows 792 publications with 34,790 citations (h-index 68), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 20 companies.
- Most recent indexed publication: 2026 · The New England journal of medicine
- Top research focus: Lung Cancer Treatments and Mutations
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 194.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Sponsor: Jonsson Comprehensive Cancer Center
- Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Sponsor: Nuvation Bio Inc.
- Ivonescimab for the Treatment of Thymic Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Industry payments
Updated 14 Oct 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20256 payments$18,850openpaymentsdata.cms.gov ↗
- Daiichi Sankyo Inc.Program year20251 payment
- Eli Lilly and CompanyProgram year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
46.6%Other antiemetics40.7%Fosaprepitant100%Part B, office-administered≥24 patientsSerotonin-3 Receptor Antagonist5.9%Palonosetron hcl84%Ondansetron hydrochloride15%Ondansetron Hcl1%Part D + Part B≥37 patientsCancer & immunology
29.4%Folate Analog Metabolic Inhibitor26.6%Pemetrexed100%Part B, office-administered≥16 patientsPlatinum-based Drug1.4%Carboplatin100%Part B, office-administered≥17 patients+ 5 more classes in this area
Musculoskeletal
18.3%RANK Ligand Inhibitor18.3%Denosumab100%Part B, office-administered≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
145 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 4243: Mutational-signature adjusted models reveal HLA-mediated depletion of antigenic mutations in non-small cell lung cancer (NSCLC)
AACR Annual Meeting
AACR2026Co-author - Abstract LB218: Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)
AACR Annual Meeting
AACR2025Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine
Article2026 - Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
The New England journal of medicine
Clinical Trial2026 - Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer6,238 citations2015
- 02
- 03Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer1,762 citations2020
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jonathan-goldman-md-0f91de68
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
profiles.ucla.edu/jonathan.goldman
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗ - ResearchGate
researchgate.net/scientific-contributions/Jonathan-W-Goldman-81022974
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
onclive.com/authors/jonathan-w-goldman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- MD
Stanford University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tlcr.amegroups.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Chair
University of California Lung Cancer Consortium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.universityofcalifornia.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- Providence Saint John's Health Center
Santa Monica (hospital affiliation)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - UCLA Jonsson Comprehensive Cancer Center
Signal Transduction and Therapeutics research program member
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancergrace.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Recurring contributing author
OncLive oncology news/commentary
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center